NASDAQ · DMAC
Healthcare · Biotechnology
$6.52
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 12:47 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
DMAC closed at $6.52 after 21 trading sessions, down 3.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $6.58 | $6.73 | $6.50 | $6.52 | 77.58K |
| Aug 20, 2026 | $6.77 | $6.90 | $6.42 | $6.52 | 130.87K |
| Aug 19, 2026 | $6.74 | $6.91 | $6.66 | $6.81 | 170.19K |
| Aug 18, 2026 | $6.52 | $6.66 | $6.48 | $6.61 | 68.93K |
| Aug 17, 2026 | $6.67 | $6.7762 | $6.56 | $6.62 | 122.97K |
| Aug 14, 2026 | $6.74 | $6.785 | $6.55 | $6.68 | 165.18K |
| Aug 13, 2026 | $6.91 | $6.98 | $6.635 | $6.75 | 111.87K |
| Aug 12, 2026 | $6.94 | $7.13 | $6.74 | $6.84 | 140.04K |
| Aug 11, 2026 | $6.67 | $7.1664 | $6.635 | $6.87 | 176.3K |
| Aug 10, 2026 | $6.64 | $6.82 | $6.44 | $6.65 | 184.61K |
| Aug 7, 2026 | $6.85 | $6.94 | $6.69 | $6.75 | 109.23K |
| Aug 6, 2026 | $6.64 | $6.85 | $6.64 | $6.77 | 76.66K |
| Aug 5, 2026 | $6.60 | $6.82 | $6.58 | $6.665 | 130.74K |
| Aug 4, 2026 | $6.60 | $6.74 | $6.49 | $6.54 | 162.74K |
| Aug 3, 2026 | $6.42 | $6.625 | $6.285 | $6.52 | 171.97K |
| Jul 31, 2026 | $6.545 | $6.545 | $6.26 | $6.34 | 99.02K |
| Jul 30, 2026 | $6.41 | $6.5656 | $6.25 | $6.51 | 301.22K |
| Jul 29, 2026 | $6.66 | $6.785 | $6.312 | $6.32 | 283.14K |
| Jul 28, 2026 | $6.74 | $6.815 | $6.515 | $6.64 | 206.7K |
| Jul 27, 2026 | $6.79 | $7.1281 | $6.65 | $6.74 | 89.71K |
| Jul 24, 2026 | $6.82 | $6.93 | $6.54 | $6.735 | 177.07K |
The latest Smart Investors Daily articles mentioning DMAC.
DMAC research
Company profile and research snapshot.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | Cantor Fitzgerald | Overweight | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 18, 2025 | Lake Street | Buy | — |
| Jul 18, 2025 | Craig-Hallum | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 11, 2026
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call August 11, 2026 8:00 AM EDTCompany ParticipantsDietrich Pauls - President, CEO & DirectorJulie...
Benzinga · Aug 11, 2026
HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.
Benzinga · Aug 10, 2026
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share
Benzinga · Jun 23, 2026
First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatmentDM199 is intended to improve maternal uterine artery blood flow
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DMAC.
